Maintenance Therapy Options for Ovarian Cancer
Barbara Norquist, MD
October 01, 2020
Dr. Norquist will discuss the role of maintenance therapy using PARP inhibitors and other agents in women with and without BRCA or other gene mutations.
About Our Speaker
Dr. Norquist is a gynecologic oncologist affiliated with the University of Washington. She is also a member of FORCE’s Scientific Advisory Board.
People concerned about hereditary ovarian cancer, cancer survivors and health care providers.